Insurance coverage rules generally follow the drugs approved use, not its form
This includes people with diabetes, high cholesterol, hypertension, or metabolic syndrome
For comprehensive cellular health support that includes skin health, consider nutrients that work together synergistically
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes For the primary endpoint, retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 weeks in TRANSCEND-T2D-1 Participants taking retatrutide 12 mg lost an average of 36.6 lbs (16.8%) No weight loss plateau was observed with retatrutide, with participants continuing their weight loss trajectory through 40 weeks 1,2 For the primary endpoint, participants taking retatrutide achieved average A1C reductions of up to 2.0%, using the efficacy estimand
doi: 10.3390/medicina57070669